I have my doubts, it just doesn't make too much sense, and please people, don’t blame Maddady or any other longs for share their thoughts, things can always go wrong, but at lease show some dignity, pointing figures will not do any good, we are all responsible for our own actions. I think that is still a hope for AFFY to be bought out.
naomi - I "bumped" a post from sfvictim entitled "Don't Forget the $500 MM NOL (Tax Loss Carryforward)" This tax loss could be a real jewel for the right company. I saw this with a company about 5 years ago and the purchasing company paid $120 million for a patent and $300 million tax loss. Please do not ask me the name of the company as I can not recall it. If I do, I will print it. I hope this info helps. Jim
Thank you, Jim, much appreciated! I see the $500 MM NLO, Tax Loss Carry-forward as strong negotiation point. I think AFFY has talked to few pharmaceutical companies. The thing is they didn't really get a detail information about the investigation, it just seem like T did this deliberately, it is not very like T. Anyway, I am holding the share and hope for the best!
AFFY disclosed some time ago that neither AFFY nor Takeda are paying the fees necessary to keep the O patents current. Based on that disclosure and Takeda's write off of its $45.8M interest in O to $0, I believe AFFY's patents for O aren't worth hardly a plug nickel. And don't forget, whoever buys AFFY (instead of its assets) also gets AFFY's litigation exposure.